NPI: 1225707771 · KERNERSVILLE, NC 27284 · Pediatrics Physician · NPI assigned 09/08/2021
Authorized official WALTON, LEEA controls 20+ related entities in our dataset. Read more
| Authorized Official | WALTON, LEEA (RCS MANAGER) |
| NPI Enumeration Date | 09/08/2021 |
Other providers sharing the same authorized official: WALTON, LEEA
| Year | Claims | Total Paid |
|---|---|---|
| 2022 | 49,557 | $1.72M |
| 2023 | 41,255 | $1.19M |
| 2024 | 23,132 | $61K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10,077 | 7,279 | $924K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9,787 | 7,054 | $612K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5,444 | 4,042 | $269K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1,917 | 1,362 | $194K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1,773 | 1,199 | $167K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1,470 | 1,067 | $140K |
| 99199 | Unlisted special service, procedure or report | 50,129 | 49,669 | $131K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,655 | 1,904 | $130K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,887 | 1,418 | $121K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,786 | 2,040 | $81K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 575 | 401 | $62K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,432 | 1,739 | $46K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 4,601 | 3,394 | $45K |
| 96127 | 6,926 | 5,180 | $34K | |
| 90461 | 3,053 | 2,220 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 101 | 71 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 42 | 36 | $2K |
| 87807 | 94 | 68 | $1K | |
| 96161 | 265 | 183 | $999.88 | |
| 87634 | 30 | 21 | $930.49 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 85 | 52 | $679.90 |
| 90674 | 1,156 | 858 | $640.02 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 42 | 36 | $567.51 |
| 92551 | 2,281 | 1,660 | $448.78 | |
| 81003 | 69 | 42 | $150.47 | |
| 85018 | 165 | 104 | $72.03 | |
| 99177 | 271 | 206 | $69.16 | |
| 99173 | 925 | 647 | $60.80 | |
| 90686 | 111 | 81 | $54.60 | |
| 36415 | Collection of venous blood by venipuncture | 19 | 13 | $44.13 |
| 36416 | 211 | 138 | $19.32 | |
| 90670 | 1,058 | 739 | $0.00 | |
| 90648 | 579 | 408 | $0.00 | |
| 90710 | 145 | 101 | $0.00 | |
| 90734 | 34 | 25 | $0.00 | |
| 90633 | 54 | 36 | $0.00 | |
| 90680 | 293 | 205 | $0.00 | |
| 90698 | 59 | 45 | $0.00 | |
| 90723 | 228 | 150 | $0.00 | |
| 99000 | 97 | 70 | $0.00 | |
| 90744 | 18 | 13 | $0.00 |